Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Current Investments: 2017-2025

Historic Cash & Current Investments for Arcus Biosciences (RCUS) over the last 9 years, with Sep 2025 value amounting to $831.0 million.

  • Arcus Biosciences' Cash & Current Investments fell 23.69% to $831.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 2.49%. This contributed to the annual value of $978.0 million for FY2024, which is 28.85% up from last year.
  • Latest data reveals that Arcus Biosciences reported Cash & Current Investments of $831.0 million as of Q3 2025, which was down 8.78% from $911.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Cash & Current Investments registered a high of $1.2 billion during Q1 2022, and its lowest value of $499.0 million during Q4 2021.
  • For the 3-year period, Arcus Biosciences' Cash & Current Investments averaged around $928.4 million, with its median value being $954.0 million (2023).
  • Within the past 5 years, the most significant YoY rise in Arcus Biosciences' Cash & Current Investments was 423.82% (2021), while the steepest drop was 32.95% (2021).
  • Arcus Biosciences' Cash & Current Investments (Quarterly) stood at $499.0 million in 2021, then spiked by 102.20% to $1.0 billion in 2022, then dropped by 24.78% to $759.0 million in 2023, then grew by 28.85% to $978.0 million in 2024, then fell by 23.69% to $831.0 million in 2025.
  • Its Cash & Current Investments was $831.0 million in Q3 2025, compared to $911.0 million in Q2 2025 and $997.0 million in Q1 2025.